Home » Topics » BioWorld Science

BioWorld Science
RSS

Lilly claims 5-HT7 antagonist for GI indications

Nov. 26, 1996

HMG-CoA reductase inhibitors for preventing second heart attack

Nov. 26, 1996

Neuregulin polypeptides described for treating retinal disorders

Nov. 26, 1996

Lilly claims new indication for olanzapine

Nov. 26, 1996

New use claimed for olanzapine

Nov. 26, 1996

Diagnostic kit for cystic fibrosis offered for licensing

Nov. 26, 1996

Human brain-derived protein kinase offered for licensing

Nov. 26, 1996

Uropontin and MAbs with potential in osteoporosis available for licensing

Nov. 26, 1996

Vaccine against H. influenzae offered for licensing

Nov. 26, 1996

Purified or recombinant proteins for HIV infection available for licensing

Nov. 26, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 29, 2026.
TROP2 ADCs progress into first-line for lung, breast cancers
BioWorld
Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
New evidence links autoimmunity to long COVID symptoms
BioWorld
Recent findings are reshaping current understanding of the post-infection landscape of SARS-CoV-2. Although previous studies had already suggested that...
Will Ovid’s golden age of KCC2 metamorph CNS?
BioWorld
The “deep dive” April 8 by Ovid Therapeutics Inc. into potassium-chloride co-transporter 2 (KCC2) research included company officials and independent experts in...
BMS-Hengrui deal strikes panic in Washington
BioWorld
On the heels of the multibillion-dollar licensing deal between Bristol Myers Squibb Co. and Jiangsu Hengrui Pharmaceuticals Co. Ltd., Chairman John Moolenaar...